HER2-expressing Cancers Clinical Trial
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
This study is being done to find out if zanidatamab when given with ALX148 is safe and can treat patients with advanced (locally advanced [inoperable] and/or metastatic) human epidermal growth factor receptor 2 (HER2)-expressing cancer.
Part 1 of the study will first evaluate the safety and tolerability and establish the recommended doses (RDs) of zanidatamab in combination with ALX148. Part 2 of the study will evaluate the anti-tumor activity of the combination of zanidatamab plus ALX148 at the RD levels in indication-specific expansion cohorts. ;